Among them, the surplus levels of IFN-γ, TNF-α, IL-1, and IL-6 have been known to be associated with the dysfunction of the blood–brain barrier (BBB) as a part of priming the neuroinflammatory process in the human brain during COVID-19 [32,54,55,56]. This evidence concerns the gene IL1A and COVID-19.